ArticleClinicoEconomics and outcomes research : CEOR2026
Economic Evaluation of Ready-to-Dilute Thiotepa (Tepylute
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Thiotepa is an intravenous alkylating agent used with other chemotherapy drugs to treat several forms of cancers. Preparation of thiotepa requires reconstitution of powder in sterile water, followed by dilution of the solution with sodium chloride 0.9% solution for injection. The reconstitution of lyophilized powdered drug formulations may pose challenges as it can increase the risk of preparation errors, leading to wastage or potential clinical consequences, and extend preparation time compared to ready-to-dilute formulations; one study found that 15% of thiotepa doses were made out-of-tolerance. Tepylute Patients and Methods: A cost offset model was created in Microsoft Excel™, the analysis compared a current scenario (thiotepa: 100% market share) with a future scenario (Tepylute Results: For a hypothetical hospital pharmacy, use of Tepylute Conclusion: Modeled results demonstrate that ready-to-dilute Tepylute
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.